Benzamycin, combining benzoyl peroxide and erythromycin, is a topical gel used in the treatment of acne vulgaris. Because of the reactivity of benzoyl peroxide, preparations containing both erythromycin and benzoyl peroxide might be unstable and degradation products could be formed. To investigate and identify these latter products, a gradient-based liquid chromatographic method using volatile mobile phase constituents was developed. Mass spectrometry data were acquired on solutions containing erythromycin and benzoyl peroxide and on freshly prepared, 2-month-old and 18-month-old samples of Benzamycin. With the reference spectra as interpretative templates, it was concluded that erythromycin undergoes oxidation, followed by benzoylation.

2003-02-01·Journal of Cutaneous Medicine and Surgery: Incorporating Medical and Surgical Dermatology4区 · 医学

A Randomized, Double-Blind, Multicenter, Parallel Group Study to Compare Relative Efficacies of the Topical Gels 3% Erythromycin/5% Benzoyl Peroxide and 0.025% Tretinoin/Erythromycin 4% in the Treatment of Moderate Acne Vulgaris of the Face

4区 · 医学

Article

作者: Rod A. W. Kunynetz ; Ken Lee Choi ; Smita Amin ; Eric Goldstein ; Charles W. Lynde ; Aditya K. Gupta

BACKGROUNDCombination treatments for acne vulgaris, such as Benzamycin (3% erythromycin/5% benzoyl peroxide) and Stievamycin (0.025% tretinoin/erythromycin 4%), reduce bacterial growth, which contributes to the inflammatory lesions typical of adolescent acne, and also decrease the epidermal cell compaction which may form the characteristic noninflammatory comedone. Both agents contain erythromycin to reduce the growth of Propionibacterium acnes in skin. Benzoyl peroxide has antibiotic activity as well as anticomedogenic properties. Tretinoin may increase the turnover of epidermal cells and loosen the cells compacted to form comedones. A combination preparation containing the two antibiotics may reduce the development of resistance; the combination preparation containing tretinoin and erythromycin will have an antibiotic effect as well as acting on differentiation.PATIENTS AND METHODSThis multicenter, randomized, double-blind, parallel group study compared the effectiveness of 3% erythromycin/5% benzoyl peroxide and 0.025% tretinoin/erythromycin 4%, each applied twice daily in patients with moderate acne vulgaris. Overall physician and patient ratings of severity of acne symptoms were performed at baseline and at weeks 2, 4, 8, and 12.RESULTSAt baseline the two treatment groups had similar disease severity. The number of papules, pustules, and comedones was reduced in both treatment groups at week 12, and the reductions were not significantly different between the two comparators. Global physician rating of improvement was significantly higher in the 3% erythromycin/5% benzoyl peroxide group compared with the 0.025% tretinoin/erythromycin 4% group; however, there was no significant difference in global patient ratings between the two treatment groups. An aggregate score was produced, for both physician rating and patient rating, by adding up individual symptom severity ratings. Compared with 0.025% tretinoin/erythromycin 4%, 3% erythromycin/5% benzoyl peroxide provided significantly greater reduction in both physician- and patient-rated severity of acne symptoms; there was a significant difference between the two groups as early as week 2. The 3% erythromycin/5% benzoyl peroxide demonstrated significantly greater reduction of erythema and scaling, as evaluated by the study physician, compared with tretinoin 0.025%/erythromycin 4%. Patients judged 3% erythromycin/5% benzoyl peroxide to have a significantly greater effect on redness, dryness, oiliness, and burning.CONCLUSIONIn moderate acne vulgaris, 3% erythromycin/5% benzoyl peroxide may provide a greater beneficial effect than 0.025% tretinoin/erythromycin 4%.

2003-01-01·Journal of Toxicology: Clinical Toxicology

Massive Venlafaxine Overdose Resulted in a False Positive Abbott AxSYM^®Urine Immunoassay for Phencyclidine

Article

作者: PE Steele ; GR Bond ; Dra Uges

CASE REPORTA 13-yr-old girl overdosed on 48 x 150 mg venlafaxine (Effexor XR). She was taking venlafaxine regularly for depression. Her only other medications included topical Benzamycin and pyridoxine 50 mg daily for acne. The Abbott AxSYM assay was positive only for phencyclidine, but GC/MS did not confirm the presence of phencyclidine. Toxilab identified only one substance, confirmed by GC/MS as venlafaxine. A serum sample obtained 3 h after her ingestion revealed a venlafaxine concentration of 24460 ng/mL and an O-desmethylvenlafaxine concentration of 3930 ng/mL, confirming the massive acute overdose (therapeutic range of venlafaxine and O-desmethylvenlafaxine together is 250-750 ng/mL). Urine spiked with 4.2 mg/mL ofvenlafaxine and 0.7 mg/mL of O-desmethylvenlafaxine was interpreted as positive with the Abbott AxSYM fluorescent polarized immunoassay for phencyclidine (readout of 28 ng/mL).CONCLUSIONVenlafaxine may cause a false positive Abbott AxSYM phencyclidine assay when present in very high concentrations. Physicians should be aware of this potential reaction when interpreting urine drug immunoassays.

项与红霉素/过氧苯甲酰相关的新闻（医药）

2022-08-23

·生物谷

PNAS：新发现！过氧化氢或有望作为促进机体神经再生的愈合制剂！

研究人员通过研究揭示了过氧化氢（hydrogen peroxide）在伤口修复和神经再生过程中的潜力和应用价值。如今，斑马鱼被广泛用于生物医学研究，其与人类共享着70%以上的基因组，且拥有着令人印象深刻的强大再生能力，加利福尼亚大学的研究者Sandra Rieger利用斑马鱼进行附肢再生和神经损伤的研究已经很多年了，近日，一篇发表在国际杂志Proceedings of the National Academy of Sciences上题为“Coordinated NADPH oxidase/hydrogen peroxide functions regulate cutaneous sensory axon de- and regeneration”的研究报告中，研究人员通过研究揭示了过氧化氢（hydrogen peroxide）在伤口修复和神经再生过程中的潜力和应用价值。文章中，研究者发现，过氧化氢或能在表皮中产生，同时还能促进受伤后机体的神经再生，这或许是一项伟大的研究发现，但当时研究人员并不知道驱动受损后机体神经再生的确切分子机制。在这项最新研究中，研究人员调查了过氧化氢如何刺激机体的神经再生，他们通过对斑马鱼机体中的特殊蛋白进行荧光标记及突变分析，并利用延时成像技术来研究这一过程。图片来源：https://www.pnas.org/doi/abs/10.1073/pnas.2115009119 研究者Rieger说道，延时成像技术提供了神经和皮肤组织之间的生物学过程和关系的详细图谱，以及这些相互作用如何影响再生，相关研究结果或许能回答皮肤如何影响神经再生的问题，因为皮肤对于产生对再生过程非常必要的因子方面非常重要。本文研究结果表明，过氧化氢会对皮肤中的表皮生长因子受体（EGFR，Epidermal Growth Factor Receptor）产生反应，EGFR对于皮肤重塑至关重要，其还能帮助伤口中的神经进行生长，这对于皮肤的恢复至关重要。研究者Rieger解释道，我们发现，如果过氧化氢在神经元中不存在的话，神经末梢也就不能再再生了，似乎神经元和皮肤需要过氧化氢来协调其神经末梢的再生过程。早在2011年，研究者Rieger就作为博士后研究员发表了其第一份研究报告，如今，近10年过去了，她推进了这一研究，并更深入地揭示了过氧化氢在刺激神经再生方面的分子功能，这或许就为未来的研究铺平了道路，从而就有望改善新型疗法来恢复机体皮肤和神经系统的功能。综上，本文研究结果表明，伤口所诱导的皮肤轴突的去再生和再生过程或许依赖于NADPH氧化酶的协调功能，该酶能介导机体神经损伤后的不同过程。（生物谷Bioon.com）原始出处： Antonio Cadiz Diaz, Natalie A. Schmidt, Mamiko Yamazaki, et al. Coordinated NADPH oxidase/hydrogen peroxide functions regulate cutaneous sensory axon de- and regeneration, Proceedings of the National Academy of Sciences (2022). DOI: 10.1073/pnas.2115009119

2022-08-07

·药明康德

全球每十人就有一位因此颜值下降…《科学》子刊揭示致病机理

▎药明康德内容团队编辑痤疮（acne），或俗称的青春痘，影响绝大部分的青少年，但许多人直到成年后都还是一直受到青春痘的困扰，实际上在全球每十个人当中就有一位有青春痘的问题，除了造成“颜值下降”外，更可能影响患者的心理健康。虽然科学家或甚至普罗大众都知道青春痘是由于皮肤油脂分泌旺盛以及细菌感染所引起，可是关于这两者如何交互作用而导致青春痘形成的详细机制仍旧不清楚。近日发表在《科学》子刊Science Immunology的一篇论文不止发现体内原本负责杀菌的巨噬细胞竟成了青春痘形成的帮凶，更是揭示了常见抗痘药物的作用机理，这对未来相关靶标药物的开发是一大助益。油脂分泌旺盛的皮肤会促进一种称为痤疮丙酸杆菌（Cutibacterium acnes）的细菌在毛囊中的增生。其中油脂成分之一的鲨烯（squalene）更是会促进细菌引起的炎症反应以及泡沫巨噬细胞（foamy macrophage）的形成。正常的巨噬细胞有助于移除多余的油脂并能够杀死细菌，但这些泡沫巨噬细胞不但无法执行这些功能，更助长痤疮丙酸杆菌的生长。为了明白造成这个现象的原因，研究人员对在背上的早期青春痘病变进行分析，通过结合单细胞与空间RNA测序，以及具超高解析度的Seq-Scope平台对空间转录组进行检查，研究人员发现了表达鲨烯氧化酶（squalene epoxidase）的毛囊上皮附近有一种表达TREM2的巨噬细胞，这种巨噬细胞带有许多脂质代谢与促炎症基因的表达。当在体外以鲨烯刺激TREM2巨噬细胞时，会导致此类巨噬细胞失去击杀痤疮丙酸杆菌的能力。科学家们发现这是由于鲨烯会抑制巨噬细胞内氧化酶的诱发，并清除细胞内氧自由基的缘故。这也解释了可促进自由基产生的过氧化苯（benzoyl peroxide）为何在临床上会具青春痘治疗的效果。除了青春痘，这种泡沫TREM2巨噬细胞也可能促进许多疾病的进展，包含了某些非酒精性脂肪肝、阿尔茨海默病、部分癌症、泡沫细胞结核病与动脉粥样硬化等。例如，在阿尔茨海默病中可发现表达TREM2的巨噬细胞（在脑部时被称为小胶质细胞）增加，而在非酒精性脂肪性肝炎中，科学家也在肝脏发现较多的TREM2巨噬细胞。有趣的是，这些疾病患者的年龄层并不重复，显示这种对脂质产生反应的巨噬细胞可以作用于生命的各个阶段。此项研究解开了TREM2巨噬细胞与像是鲨烯等非饱和脂肪在青春痘形成机制中所扮演的角色，这除了可以促使更具专一性青春痘疗法的开发外，也为其他与脂质有关的慢性疾病形成机制带来更多的了解。希望此项研究可以促进更多有效药物的发现，造福更多受这些疾病所困扰病患！药明康德为全球生物医药行业提供一体化、端到端的新药研发和生产服务，服务范围涵盖化学药研发和生产、生物学研究、临床前测试和临床试验研发、细胞及基因疗法研发、测试和生产等领域。如您有相关业务需求，欢迎点击下方图片填写具体信息。▲如您有任何业务需求，请长按扫描上方二维码，或点击文末“阅读原文/Read more”，即可访问业务对接平台，填写业务需求信息参考资料：[1] Do, Tran H et al. (2022) TREM2 macrophages induced by human lipids drive inflammation in acne lesions. Science immunology 7,73: eabo2787. DOI:10.1126/sciimmunol.abo2787[2] Acne bacteria, study suggests, thrive when skin oil turns infection-fighting cells into accomplices. Retrieved August 5, 2022 from https://www.statnews.com/2022/07/22/how-acne-bacteria-thrives-despite-immune-system/免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：本文来自药明康德内容团队，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。分享，点赞，在看，聚焦全球生物医药健康创新

基因疗法细胞疗法

2019-07-11

·GlobeNewswire

Annual General Meeting of Biofrontera AG: Biofrontera Management Board approved by large majority

Leverkusen, Germany, July 11, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today announced the results of the Annual General Meeting held on 10 July 2019. The shareholders present represented 75.88% of the registered share capital. The shareholders approved the agenda items proposed by the Management Board and Supervisory Board (published in the Federal Gazette on June 3, 2019) with a large majority. All supplementary motions and countermotions submitted by the Deutsche Balaton Group were rejected by the Annual General Meeting with a clear majority. Prof. Dr. Franca Ruhwedel was newly appointed to the Supervisory Board. In the future, she will support Biofrontera AG with her extensive financial expertise, in particular in the Audit Committee. No vote was required on agenda item 1. "The overwhelming shareholder presence at yesterday’s Annual General Meeting shows the strong interest and commitment of our shareholders. The rejection of all supplementary motions and countermotions shows that our shareholders stand united behind the Management Board and Supervisory Board. We greatly appreciate the support and would like to express our sincere thanks," said CEO Prof. Dr. Hermann Lübbert. "We see ourselves confirmed on our strategic course and will continue to work on the success of the Company with the outstanding know-how and tireless commitment of our employees". Reinhard Eyring, member of the Supervisory Board and chairman of yesterday’s meeting, added: "On behalf of the Supervisory Board, I would like to welcome Prof. Dr. Ruhwedel as a new member of the Supervisory Board of Biofrontera. My colleagues and I look forward to working together". Further information on the Annual General Meeting including the detailed voting results and the Executive Board presentation can be found at: https://www.biofrontera.com/en/annual-general-meeting.html -End- For enquiries, please contact: Biofrontera AG Thomas Schaffer, Chief Financial Officer +49 (0) 214 87 63 2 0 ir@biofrontera.com IR UK: Seton Services Toni Vallen +44 (0) 207 229 0805 IR and PR US: The Ruth Group IR: Tram Bui PR: Kirsten Thomas +1 646-536-7035 +1 508-280-6592 About Biofrontera: Biofrontera AG is a biopharmaceutical company specializing in the development and sale of dermatological drugs and medical cosmetics. The Germany-based company, with almost 200 employees worldwide, develops and markets innovative products for the care, protection and treatment of the skin. The company’s lead product is the combination of Ameluz ® , a topical prescription drug, and medical device BF-RhodoLED ® for the photodynamic therapy of certain superficial skin cancers and their precursors. Ameluz ® has been marketed in the EU since 2012 and in the United States since May 2016. In addition, the company markets AKTIPAK®, a prescription medication for the treatment of acne, and Xepi™ for the treatment of impetigo in the United States. In the EU, the company also sells the dermocosmetics series Belixos ® , which offers specialized care for damaged or diseased skin. Biofrontera is the first German founder-led pharmaceutical company to receive a centralized European and a US approval for a drug developed in-house. The Biofrontera Group was founded in 1997 by the current CEO Prof. Dr. Hermann Lübbert and is listed on the Frankfurt Stock Exchange (Prime Standard) and on the US NASDAQ.www.biofrontera.com. Forward Looking Statements: Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995 regarding the public offering and the intended use of proceeds from the offering. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate" and "intend," among others. Such forward-looking statements are based on the currently held beliefs and assumptions of the management of Biofrontera AG, which are expressed in good faith and, in their opinion, reasonable. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance, or achievements of the Company, or industry results, to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and other factors are set forth in the Registration Statement on Form F-1 filed with the SEC, including in the section "Risk Factors," and in future reports filed with the SEC. Given these risks, uncertainties and other factors, prospective investors are cautioned not to place undue reliance on these forward-looking statements. The Company does not undertake an obligation to update or revise any forward-looking statement.

100 项与红霉素/过氧苯甲酰相关的药物交易

登录后查看更多信息